Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Change in Account Payables: 2023-2025

Historic Change in Account Payables for Artiva Biotherapeutics (ARTV) over the last 2 years, with Sep 2025 value amounting to -$442,000.

  • Artiva Biotherapeutics' Change in Account Payables fell 162.78% to -$442,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$692,000, marking a year-over-year increase of 47.62%. This contributed to the annual value of $519,000 for FY2024, which is 227.21% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Change in Account Payables of -$442,000 as of Q3 2025, which was down 111.48% from -$209,000 recorded in Q2 2025.
  • Artiva Biotherapeutics' Change in Account Payables' 5-year high stood at $1.6 million during Q3 2023, with a 5-year trough of -$1.9 million in Q4 2023.
  • In the last 3 years, Artiva Biotherapeutics' Change in Account Payables had a median value of -$82,000 in 2024 and averaged -$47,444.
  • In the last 5 years, Artiva Biotherapeutics' Change in Account Payables skyrocketed by 95.73% in 2024 and then tumbled by 162.78% in 2025.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Change in Account Payables stood at -$1.9 million in 2023, then spiked by 95.73% to -$82,000 in 2024, then plummeted by 162.78% to -$442,000 in 2025.
  • Its Change in Account Payables was -$442,000 in Q3 2025, compared to -$209,000 in Q2 2025 and $41,000 in Q1 2025.